Ishikawa M, Schmidtke D W, Raskin P, Quinn C A
Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, USA.
J Diabetes Complications. 1998 Nov-Dec;12(6):295-301. doi: 10.1016/s1056-8727(98)00011-7.
Results of the initial clinical evaluation in 20 human subjects of a subcutaneously implanted microsensor-based amperometrically glycemia-monitoring system, carried out between April 1994 and June 1995, are reported. The system was based on the electrical connection ("wiring") of the reaction centers of glucose oxidase to a gold electrode and on elimination of the chemicals that interfere with glucose monitoring through their horseradish peroxidase-catalyzed oxidation by internally generated hydrogen peroxide. The sensor was finer than a 29-gauge needle and had no leachable components. Because of its high selectivity for glucose, the sensor output was virtually nil at zero glucose level. This enables prompt "one-point" in vivo calibration of the sensor with a single blood glucose sample. Microsensors were subcutaneously implanted in ten nondiabetic and ten insulin-dependent diabetes mellitus (IDDM) volunteers. All subjects underwent standard meal tests and intravenous glucose-tolerance tests (IVGTT) in addition to hourly plasma glucose measurements. The sensor signals were continuously recorded, and the glucose concentration estimates were derived by calibrating the sensor using a single blood sample (one-point calibration). Regression analysis revealed that the sensor-estimated glucose concentrations were linearly related to the plasma glucose concentrations (r2 = 0.75) over a wide glucose concentration range (2-28 mmol/L) (sensor estimate = plasma 0.96 + 0.26 mmol/L). The difference between the estimated and actual glucose concentration was -0.13+/-0.23 mmol/L [mean +/-95% confidence interval (CI), n = 546], and 95% of the estimates fell in clinically acceptable zones of the Clarke error grid. The sensing delay time was 10.4+/-2.3 min as measured by the IVGTT. The subjects reported no discomfort associated with wearing the sensors.
报告了1994年4月至1995年6月间对20名人类受试者进行的皮下植入式基于微传感器的安培法血糖监测系统初始临床评估结果。该系统基于葡萄糖氧化酶反应中心与金电极的电连接(“布线”),并通过内部产生的过氧化氢对辣根过氧化物酶催化氧化的干扰葡萄糖监测的化学物质进行消除。该传感器比29号针头更细,且没有可浸出成分。由于其对葡萄糖具有高选择性,在零葡萄糖水平时传感器输出几乎为零。这使得能够用单个血糖样本对传感器进行快速的“单点”体内校准。微传感器被皮下植入10名非糖尿病和10名胰岛素依赖型糖尿病(IDDM)志愿者体内。所有受试者除了每小时测量血浆葡萄糖外,还接受了标准餐试验和静脉葡萄糖耐量试验(IVGTT)。连续记录传感器信号,并通过使用单个血样(单点校准)对传感器进行校准来得出葡萄糖浓度估计值。回归分析显示,在较宽的葡萄糖浓度范围(2 - 28 mmol/L)内,传感器估计的葡萄糖浓度与血浆葡萄糖浓度呈线性相关(r2 = 0.75)(传感器估计值 = 血浆值0.96 + 0.26 mmol/L)。估计的葡萄糖浓度与实际葡萄糖浓度之间的差异为 -0.13 +/- 0.23 mmol/L [平均值 +/- 95%置信区间(CI),n = 546],并且95%的估计值落在克拉克误差网格的临床可接受区域内。通过IVGTT测量,传感延迟时间为10.4 +/- 2.3分钟。受试者报告佩戴传感器时没有不适。